Cytosorbents (NASDAQ:CTSO) Receives “Buy” Rating from D. Boral Capital
D. Boral Capital restated their buy rating on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research note released on Wednesday,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the medical research company’s stock. A number of other brokerages have also weighed in on CTSO. Wall Street Zen started coverage on […]
D. Boral Capital restated their buy rating on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research note released on Wednesday,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the medical research company’s stock. A number of other brokerages have also weighed in on CTSO. Wall Street Zen started coverage on […]
